Cargando…

Progression of Cognitive Decline in Parkinson’s Disease

BACKGROUND: Cognitive dysfunction is one of the most prevalent non-motor symptoms in Parkinson’s disease (PD), often experienced as more debilitating for patients and caregivers than motor problems. Therefore, a deeper understanding of the course of cognitive decline and the identification of valid...

Descripción completa

Detalles Bibliográficos
Autores principales: Roheger, Mandy, Kalbe, Elke, Liepelt-Scarfone, Inga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004891/
https://www.ncbi.nlm.nih.gov/pubmed/29914040
http://dx.doi.org/10.3233/JPD-181306
_version_ 1783332602508214272
author Roheger, Mandy
Kalbe, Elke
Liepelt-Scarfone, Inga
author_facet Roheger, Mandy
Kalbe, Elke
Liepelt-Scarfone, Inga
author_sort Roheger, Mandy
collection PubMed
description BACKGROUND: Cognitive dysfunction is one of the most prevalent non-motor symptoms in Parkinson’s disease (PD), often experienced as more debilitating for patients and caregivers than motor problems. Therefore, a deeper understanding of the course of cognitive decline and the identification of valid progression markers for Parkinson’s disease dementia (PDD) is essential. OBJECTIVE: This systematic review summarizes the current state of knowledge on cognitive decline over time by reporting effect sizes of cognitive changes in neuropsychological tests. METHODS: 1368 studies were identified by a PubMed database search and 25 studies by additionally scanning previous literature. After screening all records, including 69 full-text article reviews, 12 longitudinal studies on the progression of cognitive decline in PD met our criteria (e.g., sample size ≥50 patients). RESULTS: Only a few studies monitored cognitive decline over a longer period (>4 years). Most studies focused on the evaluation of change in global cognitive state by use of the Mini-Mental State Examination, whereas the use of neuropsychological tests was highly heterogenic among studies. Only one study evaluated patients’ cognitive performance in all specified domains (executive function, attention & working memory, memory, language, and visual-spatial function) allowing for diagnosis of cognitive impairment according to consensus guidelines. Medium to strong effect sizes could only be observed in studies with follow-up intervals of four years or longer. CONCLUSIONS: The results emphasize the need for the assessment of larger PD cohorts over longer periods of follow-up with a comprehensive neuropsychological battery.
format Online
Article
Text
id pubmed-6004891
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-60048912018-06-25 Progression of Cognitive Decline in Parkinson’s Disease Roheger, Mandy Kalbe, Elke Liepelt-Scarfone, Inga J Parkinsons Dis Review BACKGROUND: Cognitive dysfunction is one of the most prevalent non-motor symptoms in Parkinson’s disease (PD), often experienced as more debilitating for patients and caregivers than motor problems. Therefore, a deeper understanding of the course of cognitive decline and the identification of valid progression markers for Parkinson’s disease dementia (PDD) is essential. OBJECTIVE: This systematic review summarizes the current state of knowledge on cognitive decline over time by reporting effect sizes of cognitive changes in neuropsychological tests. METHODS: 1368 studies were identified by a PubMed database search and 25 studies by additionally scanning previous literature. After screening all records, including 69 full-text article reviews, 12 longitudinal studies on the progression of cognitive decline in PD met our criteria (e.g., sample size ≥50 patients). RESULTS: Only a few studies monitored cognitive decline over a longer period (>4 years). Most studies focused on the evaluation of change in global cognitive state by use of the Mini-Mental State Examination, whereas the use of neuropsychological tests was highly heterogenic among studies. Only one study evaluated patients’ cognitive performance in all specified domains (executive function, attention & working memory, memory, language, and visual-spatial function) allowing for diagnosis of cognitive impairment according to consensus guidelines. Medium to strong effect sizes could only be observed in studies with follow-up intervals of four years or longer. CONCLUSIONS: The results emphasize the need for the assessment of larger PD cohorts over longer periods of follow-up with a comprehensive neuropsychological battery. IOS Press 2018-06-13 /pmc/articles/PMC6004891/ /pubmed/29914040 http://dx.doi.org/10.3233/JPD-181306 Text en © 2018 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Roheger, Mandy
Kalbe, Elke
Liepelt-Scarfone, Inga
Progression of Cognitive Decline in Parkinson’s Disease
title Progression of Cognitive Decline in Parkinson’s Disease
title_full Progression of Cognitive Decline in Parkinson’s Disease
title_fullStr Progression of Cognitive Decline in Parkinson’s Disease
title_full_unstemmed Progression of Cognitive Decline in Parkinson’s Disease
title_short Progression of Cognitive Decline in Parkinson’s Disease
title_sort progression of cognitive decline in parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004891/
https://www.ncbi.nlm.nih.gov/pubmed/29914040
http://dx.doi.org/10.3233/JPD-181306
work_keys_str_mv AT rohegermandy progressionofcognitivedeclineinparkinsonsdisease
AT kalbeelke progressionofcognitivedeclineinparkinsonsdisease
AT liepeltscarfoneinga progressionofcognitivedeclineinparkinsonsdisease